Secukinumab eases psoriatic arthritis across disease spectrum
Patients saw greatest benefits after 16 weeks on 300mg, according to industry-funded study
24th October 2019
By Lydia Hales
Many patients with psoriatic arthritis treated with secukinumab have reduced symptoms and improved quality of life compared with placebo, according to an industry-funded study of more than 2000 patients.
The posthoc analysis used data from patients with psoriatic arthritis participating in four on-label phase three trials.
US researchers used the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and Outcome Measures in Rheumatology (GRAPPA-OMERACT) to measure improvements in a range of domains, including musculoskeletal disease